Reta

“Reta” is the shortened name for the newest, next-generation GLP-1/GIP/glucagon receptor agonist designed to help with weight management and metabolic health. It is a novel, synthetic peptide designed to target the GLP-1 receptor for the treatment of obesity and related metabolic disorders. This innovative peptide has been engineered to exhibit enhanced stability, prolonged half-life, and improved potency compared to native GLP-1. Reta has shown promising results in preclinical studies, demonstrating significant weight loss, improved glucose homeostasis, and reduced inflammation. As a potential therapeutic agent, Reta offers hope for individuals struggling with obesity and its associated comorbidities, providing a targeted approach to managing metabolic health. Requires reconstitution before use.